← Back to Screener
Twist Bioscience Corporation Common Stock (TWST)
Price$61.88
Favorite Metrics
Price vs S&P 500 (26W)98.42%
Price vs S&P 500 (4W)30.92%
Market Capitalization$3.79B
All Metrics
Book Value / Share (Quarterly)$7.44
P/TBV (Annual)3.70x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)22.75%
Cash Flow / Share (Quarterly)$-1.42
Price vs S&P 500 (YTD)91.15%
Gross Margin (TTM)51.62%
Net Profit Margin (TTM)-19.56%
EPS (TTM)$-1.27
10-Day Avg Trading Volume1.28M
EPS Excl Extra (TTM)$-1.27
Revenue Growth (5Y)33.11%
EPS (Annual)$-1.30
ROI (Annual)-16.42%
Gross Margin (Annual)50.72%
Net Profit Margin (5Y Avg)-78.56%
Cash / Share (Quarterly)$3.23
Revenue Growth QoQ (YoY)16.89%
ROA (Last FY)-12.10%
Revenue Growth TTM (YoY)18.59%
EBITD / Share (TTM)$-1.01
ROE (5Y Avg)-29.44%
Operating Margin (TTM)-34.35%
Cash Flow / Share (Annual)$-1.25
P/B Ratio8.32x
P/B Ratio (Quarterly)4.25x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)9.31x
Net Interest Coverage (TTM)-235.67x
ROA (TTM)-12.16%
EPS Incl Extra (Annual)$-1.30
Current Ratio (Annual)3.64x
Quick Ratio (Quarterly)3.08x
3-Month Avg Trading Volume1.27M
52-Week Price Return68.15%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.23
P/S Ratio (Annual)10.07x
Asset Turnover (Annual)0.59x
52-Week High$62.09
Operating Margin (5Y Avg)-84.77%
EPS Excl Extra (Annual)$-1.30
CapEx CAGR (5Y)23.19%
Tangible BV CAGR (5Y)6.46%
26-Week Price Return105.31%
Quick Ratio (Annual)3.17x
13-Week Price Return49.94%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.78x
Enterprise Value$3,645.377
Revenue / Share Growth (5Y)22.33%
Asset Turnover (TTM)0.62x
Book Value / Share Growth (5Y)0.91%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)7.08x
Pretax Margin (Annual)-20.43%
Cash / Share (Annual)$3.83
3-Month Return Std Dev72.30%
Gross Margin (5Y Avg)42.07%
Net Income / Employee (TTM)$-0
ROE (Last FY)-16.42%
Net Interest Coverage (Annual)-801.00x
EPS Basic Excl Extra (Annual)$-1.30
Receivables Turnover (TTM)8.76x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.27
Receivables Turnover (Annual)8.19x
ROI (TTM)-16.58%
P/S Ratio (TTM)9.69x
Pretax Margin (5Y Avg)-79.70%
Revenue / Share (Annual)$6.30
Tangible BV / Share (Annual)$7.58
Price vs S&P 500 (52W)33.52%
Year-to-Date Return95.08%
5-Day Price Return7.79%
EPS Normalized (Annual)$-1.30
ROA (5Y Avg)-23.35%
Net Profit Margin (Annual)-20.63%
Month-to-Date Return30.22%
Cash Flow / Share (TTM)$-3.08
EBITD / Share (Annual)$-1.06
Operating Margin (Annual)-36.18%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-29.42%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.27
P/TBV (Quarterly)4.38x
P/B Ratio (Annual)3.59x
Inventory Turnover (TTM)6.71x
Pretax Margin (TTM)-19.33%
Book Value / Share (Annual)$7.80
Price vs S&P 500 (13W)47.56%
Beta2.28x
Revenue / Share (TTM)$6.41
ROE (TTM)-16.58%
52-Week Low$23.30
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.24
4.24
4.24
4.24
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TWSTTwist Bioscience Corporation Common Stock | 9.69x | 18.59% | 51.62% | — | $61.88 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 11.09x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Twist Bioscience Corp develops a semiconductor-based DNA synthesis platform that manufactures synthetic DNA on silicon, enabling faster production and lower costs than traditional methods. This proprietary technology supports high-throughput, cost-effective synthesis and accelerates innovation across research and development. The company generates revenue from three geographic regions—Americas, EMEA, and APAC—with the majority coming from North America.